Effect of Salbutamol on Oxygen Levels in COPD Patients During Lung Surgery
Assessment of Salbutamol Effect on Arterial Oxygenation in COPD Patients During One-lung Ventilation
NA · Yonsei University · NCT05914285
This study is testing if inhaling salbutamol can help improve oxygen levels in COPD patients during lung surgery when only one lung is being used for breathing.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Yonsei University (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05914285 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of inhaled salbutamol on arterial oxygenation in patients with chronic obstructive pulmonary disease (COPD) undergoing one-lung ventilation during thoracic surgery. One-lung ventilation can lead to significant hypoxemia due to ventilation-perfusion mismatch, particularly in COPD patients. The study hypothesizes that salbutamol, a beta2-agonist, will improve oxygenation by reducing pulmonary vascular resistance in the ventilated lung. Participants will receive either inhaled salbutamol or normal saline to assess its effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 40 to 80 with moderate to severe COPD scheduled for pulmonary lobectomy.
Not a fit: Patients with severe heart conditions, recent myocardial infarction, or significant renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance oxygenation and reduce complications during lung surgeries for COPD patients.
How similar studies have performed: While the specific use of salbutamol in this context may be novel, similar studies have shown that beta2-agonists can improve pulmonary function in COPD patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient age 40\~80yrs, scheduled for videoscope-assisted pulmonary lobectomy * American Society of Anesthesiologists Class III 또는 IV * Moderate or more severe COPD according to GOLD criteria (FEV1/FVC\<70%, FEV1\<80%) Exclusion Criteria: * New York Heart Association class \>II * AST level ≥100 IU/mL or ALT ≥ level 50 IU/L * Creatinine clearance \< 30mL/min * History of severe coronary artery occlusive disease, unstable angina, or recent myocardial infarction within 6 months * History of pulmonary hypertension or pulmonary edema * History of cerebrovascular accident within 3 months
Where this trial is running
Seoul
- Severance Hospital, Yonsei University Health System — Seoul, Korea, Republic of (RECRUITING)
Study contacts
- Principal investigator: Young Jun Oh — Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University Health System, Seoul, Korea
- Study coordinator: Young Jun Oh
- Email: yjoh@yuhs.ac
- Phone: 82-2-2224-1636
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: One-lung Ventilation, Chronic Obstructive Pulmonary Disease